Known more for its use as party drug, ketamine can provide a lifeline for people experiencing distressing mental health ...

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation ...

Have you noticed that people seem to be more open to talking and learning about death? In recent years, people have been exposed to a significant increase in death education. They are more accepting ...

Harrow (HROW) to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and ...

Tranyelle Harshman fatally shot her four children and herself while in “an altered or dissociative mental state” induced by ...

Harrow entered into an agreement to acquire Melt Pharmaceuticals and plans to submit a new drug application for MELT-300, ...

The Mucosal Atomization Device Market is on a steady growth trajectory, expected to expand from USD 609.0 million in 2025 to ...